How many drugs treat Absence seizure?

Drug Landscape tracks 10 marketed treatments for Absence seizure (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/absence-seizure.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Absence seizure — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Absence seizure (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Absence seizure, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Depakene	valproic acid	Generic (originally Abbott/AbbVie)	Anti-epileptic Agent [EPC]	Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2	1978-02-28
Ativan	lorazepam	Generic (originally Wyeth/Pfizer)	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver	1977-09-30
Klonopin	clonazepam	Generic (originally Roche)	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel	1975-06-04
Zarontin	Ethosuximide	Pfizer	Succinimide	Voltage-dependent T-type calcium channel subunit alpha-1G	1960-01-01
Celontin	METHSUXIMIDE	Pfizer	Anti-epileptic Agent	Voltage-gated T-type calcium channel	1957-01-01
Diamox	ACETAZOLAMIDE	Teva	Carbonic Anhydrase Inhibitor [EPC]	Carbonic anhydrase	1953-01-01
Klonopin	Klonopin	Par Pharmaceutical, Inc.		GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel
Epilim	sodium valproate	Sanofi		Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2
Divalproex	Divalproex	University of Chicago		Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2
mesuximide	mesuximide	Assistance Publique - Hôpitaux de Paris		Voltage-gated T-type calcium channel

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Absence seizure
· 3 drugs in Absence seizure
Generic (originally Abbott/AbbVie) · 1 drug in Absence seizure
Generic (originally Roche) · 1 drug in Absence seizure
Generic (originally Wyeth/Pfizer) · 1 drug in Absence seizure
Par Pharmaceutical, Inc. · 1 drug in Absence seizure
Sanofi · 1 drug in Absence seizure
Teva · 1 drug in Absence seizure
University of Chicago · 1 drug in Absence seizure
Assistance Publique - Hôpitaux de Paris · 1 drug in Absence seizure

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Absence seizure:

Cite this brief

Drug Landscape (2026). Absence seizure — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/absence-seizure. Accessed 2026-06-10.

Absence seizure full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing